Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Eli Lilly has committed to setting a new standard for on-screen representation of common chronic diseases, and it walked the walk with its recent sponsorship of a segment on “Project Runway.” In the ...

Oct 8 (Reuters) - Telehealth company HealthTap said on Wednesday it is joining Eli Lilly's (LLY.N), opens new tab digital healthcare platform, LillyDirect, to offer virtual diabetes management ...

Oct 15 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday ...

Eli Lilly: Was I Too Cautious? We don't get everything right, do we? While I nailed the upgrade in Eli Lilly and Company (NYSE:LLY) stock in my last write-up in August, some of you might contend that ...

Lily-Rose Depp attended Matthieu Blazy’s first collection for Chanel during Paris Fashion Week. Corbis via Getty Images The industry has been abuzz about the recent shake-up amongst creative directors ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the company said early Thursday, in a sign it might be edging closer to getting the ...

Mounjaro is sold in two injectable dosage forms with the price ranging from Rs 14,000 to Rs 17,500 per month. Eli Lilly's weight-loss drug Mounjaro (tirzepatide) became the second-most sold medicine ...

Dogs specially trained to pick up the scent of human remains did not find two children who have been missing from rural Nova Scotia for more than five months, RCMP announced Wednesday as they renewed ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. From late 2020 to the summer of 2024, Eli Lilly & Co.

Last week will likely be remembered as the one in which pharma frustrations with the UK boiled over. MSD's decision to pull back from a £1 billion ($1.35 billion) investment in the country was bad ...